Press release
Myopic macular degeneration Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Bayer, Regeneron Pharmaceuticals, Roche
Myopic macular degeneration Market Analysis
Emerging therapies for Myopic Macular Degeneration, including EYLEA (aflibercept), VABYSMO (faricimab), and others, are anticipated to drive growth in the Myopic Macular Degeneration market in the coming years.
DelveInsight has released a comprehensive report titled "Myopic Macular Degeneration - Market Insights, Epidemiology, and Market Forecast-2034," providing detailed analysis of the disease, its historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Myopic macular degeneration market report @ https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Myopic macular degeneration Market Report:
In 2022, the Myopic Macular Degeneration (MMD) market across the seven major markets (7MM) was largely driven by anti-VEGF therapies and standard care, generating approximately USD 734 million. Market growth is expected to be moderate during the forecast period (2023-2034) due to a relatively limited pipeline of emerging treatments.
DelveInsight reports that Japan accounted for the largest share of diagnosed MMD cases in the 7MM, representing 49% of the total, followed by the United States with roughly 27% of cases in 2022. Epidemiological data indicates that MMD disproportionately affects females across the 7MM, potentially influenced by hormonal, genetic, or environmental factors. Choroidal neovascularization (CNV), a severe complication of pathological myopia, constituted about 5% of all diagnosed MMD cases in 2022.
Leading pharmaceutical companies, including Roche, Bayer, and Regeneron Pharmaceuticals, are actively developing new therapies to address gaps in care and improve outcomes for MMD patients worldwide. DelveInsight estimates that approximately 4.1 million individuals were diagnosed with MMD across the 7MM in 2022, with numbers projected to rise during the forecast period. In the United States alone, around 1.1 million people were diagnosed with MMD in 2022, with the figure expected to grow at a notable compound annual growth rate (CAGR) through 2034.
In 2024, the U.S. FDA approved several treatments for MMD:
*
Byooviz (ranibizumab-nuna): A biosimilar to Lucentis, approved for various retinal conditions including myopic choroidal neovascularization (mCNV).
*
Cimerli (ranibizumab-eqrn): Another Lucentis biosimilar indicated for mCNV, providing a more cost-effective treatment option.
*
Susvimo (ranibizumab injection): An implantable device delivering ranibizumab continuously over six months, reducing injection frequency for patients with wet AMD and mCNV.
Key companies such as Bayer/Regeneron, Roche, and others continue to evaluate new therapies to enhance the MMD treatment landscape. Promising treatments include EYLEA (aflibercept), VABYSMO (faricimab), and additional emerging therapies.
Myopic macular degeneration Overview
Myopia is a vision condition in which distant objects appear blurred while close objects remain clear. High myopia is a more severe form of nearsightedness and significantly increases the risk of serious eye complications, such as myopic macular degeneration, posterior staphyloma, and retinal detachment, all of which can result in permanent vision loss.
As myopia progresses to pathological myopia, it creates a higher likelihood of eye complications, including Myopic Macular Degeneration (MMD). MMD involves the gradual deterioration of the macula-the central portion of the retina responsible for sharp, detailed vision. The elongation of the eyeball, thinning of the choroid, and structural changes in the retina make the macula more vulnerable to damage, resulting in MMD. Clinical features of this condition may include staphyloma, lacquer cracks, Fuchs' spots, or chorioretinal atrophy in the posterior pole of the eye.
Myopic macular degeneration Market Outlook
Myopic maculopathy, also referred to as Myopic Macular Degeneration or myopic retinopathy, encompasses conditions such as macular atrophy, lacquer cracks, and choroidal neovascularization (mCNV), with risk influenced by factors like age and axial eye length. Interventions such as low-concentration atropine and optical devices are employed to slow the progression of myopia.
At present, there is no definitive treatment for myopic maculopathy, except for managing mCNV, underscoring the pressing need for new therapeutic options. Current treatments for Myopic Macular Degeneration are largely adapted from wet age-related macular degeneration therapies, utilizing anti-VEGF agents such as LUCENTIS (whose patent has expired) and EYLEA.
Discover how the Myopic macular degeneration market is rising in the coming years @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Myopic Macular Degeneration Marketed Drugs
*
EYLEA (aflibercept): Bayer/Regeneron Pharmaceuticals
Myopic macular degeneration Emerging Drugs
*
VABYSMO (faricimab): Roche
Scope of the Myopic macular degeneration Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Myopic macular degeneration Companies: Bayer/Regeneron Pharmaceuticals, Roche, and others
*
Key Myopic macular degeneration Therapies: EYLEA (aflibercept), VABYSMO (faricimab), and others
*
Myopic macular degeneration Therapeutic Assessment: Myopic macular degeneration current marketed and Myopic macular degeneration emerging therapies
*
Myopic macular degeneration Market Dynamics: Myopic macular degeneration market drivers and Myopic macular degeneration market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Myopic macular degeneration Unmet Needs, KOL's views, Analyst's views, Myopic macular degeneration Market Access and Reimbursement
To know what's more in our Myopic macular degeneration report, visit https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Myopic macular degeneration Market Report:
*
Myopic macular degeneration market report covers a descriptive overview and comprehensive insight of the Myopic macular degeneration Epidemiology and Myopic macular degeneration market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
*
The Myopic macular degeneration market report provides insights into the current and emerging therapies.
*
The Myopic macular degeneration market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Myopic macular degeneration market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myopic macular degeneration market.
Got queries? Click here to know more about the Myopic macular degeneration market Landscape [https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Myopic macular degeneration Patient Share (%) Overview at a Glance
5. Myopic macular degeneration Market Overview at a Glance
6. Myopic macular degeneration Disease Background and Overview
7. Myopic macular degeneration Epidemiology and Patient Population
8. Country-Specific Patient Population of Myopic macular degeneration
9. Myopic macular degeneration Current Treatment and Medical Practices
10. Unmet Needs
11. Myopic macular degeneration Emerging Therapies
12. Myopic macular degeneration Market Outlook
13. Country-Wise Myopic macular degeneration Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Myopic macular degeneration Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Myopic macular degeneration Market Outlook 2034 [https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Related Reports:
Myopic macular degeneration Pipeline Insights, DelveInsight
"Myopic macular degeneration Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myopic macular degeneration market. A detailed picture of the Myopic macular degeneration pipeline landscape is provided, which includes the disease overview and Myopic macular degeneration treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopic-macular-degeneration-market-analysis-epidemiology-insights-therapies-companies-by-delveinsight-bayer-regeneron-pharmaceuticals-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myopic macular degeneration Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Bayer, Regeneron Pharmaceuticals, Roche here
News-ID: 4190149 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Myopic
Myopic Macular Degeneration Market to Grow at 8.0% CAGR by 2034
Introduction
Myopic Macular Degeneration (MMD), also referred to as myopic maculopathy or pathological myopia, is a progressive retinal condition that occurs in individuals with high myopia. Characterized by degeneration of the macula, choroidal neovascularization, and retinal atrophy, MMD is a leading cause of irreversible vision loss in working-age adults, particularly in East Asia.
The rapid rise in global myopia prevalence-driven by urbanization, lifestyle changes, and increased screen time-has dramatically expanded the patient…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
Myopic macular degeneration Market: Epidemiology, Therapies, Companies, DelveIns …
Myopic macular degeneration therapies, such as EYLEA (aflibercept), VABYSMO (faricimab), and others, are expected to boost the Myopic macular degeneration Market in the upcoming years.
DelveInsight has launched a new report on "Myopic macular degeneration - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Myopic macular degeneration, historical and forecasted epidemiology as well as the Myopic macular degeneration market trends in the United States, EU5 (Germany,…
Myopic Macular Degeneration Market Forecasted to Surge in Coming Years, 2024-203 …
The Key Myopic Macular Degeneration Companies in the market include - Roche, Bayer, Regeneron Pharmaceuticals, and others.
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth…
Myopic Macular Degeneration Market Report 2034:- Latest FDA, EMA, PDMA, Pipeline …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology and the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Myopic Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Myopic…
Myopic Lenses Market Overview and Regional Outlook Study 2016 - 2030
the Myopic Lenses market is anticipated to generate a revenue of $5,361.10 million and grow at a CAGR of 7.6% throughout the forecast timeframe from 2022 to 2030.
The Global Myopic Lenses Market is fueled by various factors, according to a detailed assessment explained in the report. This study shows how important in-depth analysis should be, and how it greatly affects the quality of information provided to the readers. Further,…
